DUBLIN--(BUSINESS WIRE)--The "Transcatheter Aortic Valve Implantation (TAVI) Market by Procedure (Transfemoral Implantation, Transapical Implantation, and Transaortic Implantation) - Global Opportunity Analysis and Industry Forecast, 2018-2025" report has been added to ResearchAndMarkets.com's offering.
According to the report, the market revenue was valued at $2,761 million in 2017 and is expected to reach $8,138 million by 2025, growing at a CAGR of 13.8% from 2018 to 2025.
The volume market was valued at 107,011 units in 2017 and is expected to reach 337,778 units by 2025, growing at a CAGR of 14.8% from 2018 to 2025.
The need of transcatheter aortic valve implantation is on the rise due to the increase in prevalence of aortic stenosis.
The TAVI market is in its growth phase, and is mainly driven by rise in prevalence of aortic stenosis and increase in geriatric population.
In addition, increase in adoption rate of transcatheter aortic implantation along with new device approvals and improvement of healthcare infrastructure in developing countries are other factors that fuel the market growth.
However, high cost of transcatheter aortic valve and its implantation procedures, along with lack of reimbursement and stringent approvals for these devices, hamper the growth of the TAVI market.
Mainly, three types of approaches are used to implant the transcatheter aortic valve in patients-transfemoral, transapical, and transaortic implantation.
Transfemoral implantation was the highest revenue-generating segment in the global market (in terms of value and volume) in 2017, as it does not require a chest incision.
Furthermore, transaortic segment is projected to grow at the highest CAGR of 19.1% (in terms of value) and 20.1% (in terms of volume) by 2025, due to positive outcomes of several clinical trials.
Company Profiles
- Abbott Laboratories
- Boston Scientific Corporation
- Bracco S.P.A.
- Edwards Lifesciences Corporation
- Jenavalve Technology, Inc.
- JC Medical, Inc.
- Medtronic Plc.
- Meril Life Sciences Pvt. Ltd.
- NVT AG
- Venus Medtech, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/d6v87z/the_global?w=4
